Abera Bioscience AB (NGM:ABERA)
7.60
-0.70 (-8.43%)
At close: Sep 8, 2025
Abera Bioscience AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2020 |
Cash & Equivalents | 7.95 | 6.09 | 3.32 | 15.43 | 11.95 | 0.9 | Upgrade |
Cash & Short-Term Investments | 7.95 | 6.09 | 3.32 | 15.43 | 11.95 | 0.9 | Upgrade |
Cash Growth | 202.44% | 83.49% | -78.50% | 29.13% | 1224.40% | -65.97% | Upgrade |
Other Receivables | 0.87 | 0.65 | 0.77 | 0.77 | 0.3 | 0.18 | Upgrade |
Receivables | 0.87 | 0.65 | 0.77 | 0.77 | 0.3 | 0.18 | Upgrade |
Prepaid Expenses | 2.18 | 3.91 | 3.38 | 1.49 | 0.19 | - | Upgrade |
Other Current Assets | - | - | - | -0 | - | - | Upgrade |
Total Current Assets | 10.99 | 10.65 | 7.46 | 17.69 | 12.44 | 1.08 | Upgrade |
Property, Plant & Equipment | 1.05 | 1.07 | - | - | - | - | Upgrade |
Long-Term Deferred Charges | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 | 1.89 | Upgrade |
Other Long-Term Assets | -0 | -0 | - | - | 17.05 | - | Upgrade |
Total Assets | 13.92 | 13.6 | 9.35 | 19.57 | 31.37 | 2.97 | Upgrade |
Accounts Payable | 0.91 | 1.23 | 2.2 | 1.67 | 0.99 | 0.13 | Upgrade |
Accrued Expenses | 0.86 | 0.95 | 1.23 | 0.97 | 1.17 | 1.36 | Upgrade |
Other Current Liabilities | 4.38 | 2.77 | 0.27 | 0.16 | 0.07 | 1.05 | Upgrade |
Total Current Liabilities | 6.15 | 4.95 | 3.69 | 2.8 | 2.22 | 2.54 | Upgrade |
Other Long-Term Liabilities | - | - | - | -0 | -0 | - | Upgrade |
Total Liabilities | 6.15 | 4.95 | 3.69 | 2.8 | 2.22 | 2.54 | Upgrade |
Common Stock | 1.23 | 1.23 | 1.16 | 1.03 | 0.84 | 0.56 | Upgrade |
Additional Paid-In Capital | 68.82 | 68.89 | 64.86 | 59.39 | 52.49 | 14.97 | Upgrade |
Retained Earnings | -62.28 | -61.46 | -60.36 | -44.11 | -24.73 | -15.56 | Upgrade |
Comprehensive Income & Other | - | - | 0 | 0.47 | 0.56 | 0.47 | Upgrade |
Shareholders' Equity | 7.77 | 8.66 | 5.66 | 16.78 | 29.15 | 0.43 | Upgrade |
Total Liabilities & Equity | 13.92 | 13.6 | 9.35 | 19.57 | 31.37 | 2.97 | Upgrade |
Net Cash (Debt) | 7.95 | 6.09 | 3.32 | 15.43 | 11.95 | 0.9 | Upgrade |
Net Cash Growth | 202.44% | 83.49% | -78.50% | 29.13% | 1224.40% | -65.97% | Upgrade |
Net Cash Per Share | 0.34 | 0.39 | 0.25 | 1.32 | 1.17 | 0.13 | Upgrade |
Filing Date Shares Outstanding | 15.35 | 15.35 | 14.46 | 12.91 | 11.57 | 10.46 | Upgrade |
Total Common Shares Outstanding | 15.35 | 15.35 | 14.46 | 12.91 | 11.57 | 6.97 | Upgrade |
Working Capital | 4.84 | 5.7 | 3.77 | 14.89 | 10.21 | -1.46 | Upgrade |
Book Value Per Share | 0.51 | 0.56 | 0.39 | 1.30 | 2.52 | 0.06 | Upgrade |
Tangible Book Value | 7.77 | 8.66 | 5.66 | 16.78 | 29.15 | 0.43 | Upgrade |
Tangible Book Value Per Share | 0.51 | 0.56 | 0.39 | 1.30 | 2.52 | 0.06 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.